IRVING,
Texas, March 7, 2023 /PRNewswire/ -- Caris
Life Sciences®(Caris), the leading molecular science and
technology company actively developing and delivering innovative
solutions to revolutionize healthcare, today announced a strategic
research partnership with Incyte Corporation (NASDAQ:INCY) to
augment precision medicine approaches for Incyte's oncology
pipeline.
This partnership with Incyte will leverage
Caris' leading molecular science and technology solutions
Caris' unique platform combines data from whole exome
sequencing, whole transcriptome sequencing, protein analysis, and
proprietary AI models and signatures to improve patient outcomes
through advancement of personalized medicine. The partnership will
apply Caris' data and analytics tools, comprehensive molecular
tissue and liquid profiling services, and clinical trial enrollment
program capabilities across two therapeutic programs initially,
with the option for Incyte to expand to four total programs.
"This partnership with Incyte will leverage Caris' leading
molecular science and technology solutions to support Incyte's
oncology research and development efforts," said David Spetzler, M.S., Ph.D., MBA, President and
Chief Scientific Officer of Caris Life Sciences. "The aggregate
strength of our platform, which provides patient level DNA and RNA
data both in tissue and blood, may help to better identify
and predict patient response to therapy, which in turn may
accelerate clinical trial enrollment, optimize clinical positioning
and potentially enhance technical and regulatory
success."
Under the terms of the agreement, Incyte will leverage Caris'
data insights and analytics capabilities to discover novel
biomarkers and optimize clinical positioning strategies for its
oncology programs. For drug candidates developed under the
collaboration, patients enrolled in Incyte-led clinical trials will
undergo longitudinal testing with Caris' comprehensive tissue and
liquid molecular profiling assays. Incyte will also leverage Caris'
biomarker-driven patient selection for clinical trials including
options to partner on developing companion diagnostics for programs
in the partnership.
"Incyte is committed to identifying new treatments for cancer
patients using approaches exploring both single agents and
combinations of targeted therapies and immunotherapies in areas of
high unmet medical need," said Jeff
Jackson, Ph.D., Vice President, Translational Sciences at
Incyte. "Our partnership with Caris will bring a comprehensive
suite of precision medicine capabilities to augment Incyte's
success in developing key programs in our robust oncology
portfolio."
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading
molecular science and technology company actively developing and
delivering innovative solutions to revolutionize healthcare and
improve patient outcomes. Through comprehensive molecular profiling
(Whole Exome and Whole Transcriptome Sequencing) and the
application of advanced artificial intelligence (AI) and machine
learning algorithms, Caris has created the large-scale
clinico-genomic database and cognitive computing needed to analyze
and unravel the molecular complexity of disease. This information
provides an unmatched resource and the ideal path forward to
conduct the basic, fundamental research to accelerate discovery for
detection, diagnosis, monitoring, therapy selection and drug
development to improve the human condition.
With a primary focus on cancer, Caris' suite of market-leading
molecular profiling offerings assesses DNA, RNA and proteins to
reveal a molecular blueprint that helps patients, physicians and
researchers better detect, diagnose and treat patients. The
company's latest advancement, Caris Assure™, is a
blood-based, circulating nucleic acids sequencing (cNAS) assay that
combines comprehensive molecular analysis (Whole Exome and Whole
Transcriptome Sequencing from blood) and serial monitoring – making
it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Tokyo, Japan and
Basel, Switzerland. Caris or its
distributors provide services in the U.S., Europe, Asia
and other international markets. To learn more, please
visit CarisLifeSciences.com or follow us
on LinkedIn.
Caris Life Sciences Media Contact:
Lisa Burgner
corpcomm@carisls.com
214.294.5606
Caris Life Sciences Business Development Contact:
Brian Lamon, Ph.D.
Chief Business Officer, Head of BioPharma Business Development
blamon@carisls.com
609.955.8883
View original content to download
multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-and-incyte-enter-into-broad-precision-medicine-partnership-to-advance-incytes-oncology-pipeline-301764183.html
SOURCE Caris Life Sciences